Search
Novocure Ltd
NVCRAdd to Watchlist
16.310USD
-0.720-4.23%
Close 07-28 16:00（ET）Quotes delayed by 15 min
1.89BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-27The current earnings forecast score of Novocure Ltd is 7.75, ranking 124 out of 199 in the Healthcare Equipment & Supplies industry. The average price target is 24.00, with a high of 42.00 and a low of 14.50.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
28.833
Target Price
+63.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Novocure Ltd
NVCR
7
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
29
1
2
3
...
22
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Novocure Ltd's expected revenue for the next quarter?
Novocure Ltd's expected revenue is 178.96M.
What is Novocure Ltd's price target?
Analysts forecast that Novocure Ltd's price target is USD 24.00, with the highest forecast at USD 42.00 and the lowest forecast at USD 14.50.
How have Novocure LtdNVCR's recent earnings per share performed?
The market expectation was USD -0.13, while Novocure LtdNVCR's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -0.30.
What is the analyst rating for Novocure Ltd?
Based on the ratings of Novocure Ltd's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.